Health Care
Blog
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Drug Innovation
PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls
PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027. The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
Commentary
Make Hospital Prices Transparent Again
In just a few days, President-elect Trump will reclaim the Oval Office. High on his list of priorities should be enforcing the hospital price transparency rules he announced during his first term. The rules, which took effect in 2021, require hospitals to publish prices for 300 common procedures — from ...
Commentary
Republicans can make Medicaid work again
The incoming Trump administration and Republican-controlled Congress are looking to rein in Medicaid, the health insurance entitlement that consumed a record 10% of the federal budget in 2023 despite delivering substandard care to its 79.4 million enrollees. Democrats are lining up to denounce the GOP’s plans, which they claim will ...
Biosimilars
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
Commentary
Make Hospitals Competitive Again by Reining in Spending
The United States spent $4.9 trillion on healthcare in 2023, according to figures published last month by the federal government. That’s an increase of 7.5% relative to 2022. What’s behind this astounding spending growth? It’s largely hospital care. Read the entire op-ed here.
Commentary
Medicare should cover anti-obesity drugs
The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s. Congress is also considering such a move. Expanding coverage to these patient groups makes sense. Read the entire op-ed here.
Commentary
Keep Your Price Controls Off Weight-Loss Drugs
Biden administration is proposing that Medicare and Medicaid cover Ozempic and other GLP-1 drugs for weight loss. It’s unclear what the Trump administration will do with its predecessor’s proposal. Democrats may be trying to goad Medicare under Trump into slapping price controls on GLP-1s — something progressives have long wanted ...
Commentary
Obamacare is just overly expensive catastrophic health insurance
Democrats are warning of a surge in the number of uninsured if costly enhanced subsidies for exchange coverage expire as planned at the end of next year. But exchange coverage is borderline useless to many enrollees. It requires beneficiaries to fork over huge sums before it kicks in and confines ...
Commentary
Enhanced Obamacare Subsidies Define Taking Without Giving
The Congressional Budget Office (CBO) is projecting that some 2.2 million people will become uninsured in 2026 if the enhanced premium subsidies that Democrats green-lit for exchange coverage expire as scheduled at the end of next year. Eventually, the CBO says, the end of those subsidies will result in 3.8 ...
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls
PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027. The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
Make Hospital Prices Transparent Again
In just a few days, President-elect Trump will reclaim the Oval Office. High on his list of priorities should be enforcing the hospital price transparency rules he announced during his first term. The rules, which took effect in 2021, require hospitals to publish prices for 300 common procedures — from ...
Republicans can make Medicaid work again
The incoming Trump administration and Republican-controlled Congress are looking to rein in Medicaid, the health insurance entitlement that consumed a record 10% of the federal budget in 2023 despite delivering substandard care to its 79.4 million enrollees. Democrats are lining up to denounce the GOP’s plans, which they claim will ...
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
Make Hospitals Competitive Again by Reining in Spending
The United States spent $4.9 trillion on healthcare in 2023, according to figures published last month by the federal government. That’s an increase of 7.5% relative to 2022. What’s behind this astounding spending growth? It’s largely hospital care. Read the entire op-ed here.
Medicare should cover anti-obesity drugs
The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s. Congress is also considering such a move. Expanding coverage to these patient groups makes sense. Read the entire op-ed here.
Keep Your Price Controls Off Weight-Loss Drugs
Biden administration is proposing that Medicare and Medicaid cover Ozempic and other GLP-1 drugs for weight loss. It’s unclear what the Trump administration will do with its predecessor’s proposal. Democrats may be trying to goad Medicare under Trump into slapping price controls on GLP-1s — something progressives have long wanted ...
Obamacare is just overly expensive catastrophic health insurance
Democrats are warning of a surge in the number of uninsured if costly enhanced subsidies for exchange coverage expire as planned at the end of next year. But exchange coverage is borderline useless to many enrollees. It requires beneficiaries to fork over huge sums before it kicks in and confines ...
Enhanced Obamacare Subsidies Define Taking Without Giving
The Congressional Budget Office (CBO) is projecting that some 2.2 million people will become uninsured in 2026 if the enhanced premium subsidies that Democrats green-lit for exchange coverage expire as scheduled at the end of next year. Eventually, the CBO says, the end of those subsidies will result in 3.8 ...
